Stivarga® (regorafenib) is now available supplied as four 21-count bottles, replacing the previous packaging of three 28-count bottles.
Stivarga is a kinase inhibitor indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.
It is also indicated for locally advanced, unresectable or metastatic gastrointestinal stromal tumor in patients who have been previously treated with imatinib mesylate and sunitinib malate; and for patients with hepatocellular carcinoma who have been previously treated with sorafenib.
The new packaging was designed to help accommodate dispensing. Stivarga is supplied as 40mg strength tablets with a recommended dose of 160mg (four tablets) once daily for the first 21 days of each 28-day cycle.
“The streamlined packaging is a welcome change to help improve the dispensing experience for pharmacists and physicians,” said Ray Bailey, RPh, Director of Pharmacy of Florida Cancer Specialists and Research.
Bayer introduces updated packaging for Stivarga® (regorafenib) to help accommodate dispensing. [press release]. Whippany, NJ: Bayer; June 23, 2021.
This article originally appeared on MPR